Experimental Drug Daraxonrasib Doubles Pancreatic Cancer Survival Time in Trial

Executive Briefing

• Demonstrates doubling of average survival to 13.2 months versus 6.7 months on chemotherapy in 500-patient phase 3 trial
• Targets KRAS gene mutation found in over 90% of pancreatic cancers and present across lung, colon, ovarian, and other cancers
• Receives FDA fast-track designation with expanded access program now allowing use outside clinical trials
• Reports significantly lower toxicity than chemotherapy, with side effects including rash and mouth sores
• Signals potential shift away from chemotherapy as first-line treatment if further research confirms superiority